TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05912127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported fixed full arch prosthesis
Description: the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported fixed full arch prosthesis
Description: the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
Study: NCT06151691

Intervention type: OTHER
Intervention: Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
Description: Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test.
Study: NCT06131710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated Strengthening Exercises
Description: Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated Strengthening Exercises
Description: Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Strengthening Exercises
Description: Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
Study: NCT04927312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06947386
Description: Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 0.5 g solution for injection.
Study: NCT05742386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training
Description: Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training enhanced with standing orders optimization
Description: Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative.
Study: NCT04986501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MucoPEG
Description: Experimental

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotene
Description: Active Comparator
Study: NCT05785611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally once daily
Study: NCT04936321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT for Insomnia
Description: The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT for Pain Management
Description: The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered CBT for Pain Management
Description: The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered Sleep Education
Description: The program delivers publicly available information about sleep.
Study: NCT03883945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIV001
Description: intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIV001
Description: intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIV001
Description: intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIV001
Description: intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: intradermal injection
Study: NCT05064241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to Genetic Counselor for answering questions
Description: A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
Study: NCT05841472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
Description: * 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles.
Study: NCT04894799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Control facilitation exercises
Description: all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
Study: NCT04937023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid gel
Description: Following scaling and root planing in intrabony defects UDCA gel will be injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic acid gel
Description: Following scaling and root planing in intrabony defects UDCA gel will be injected
Study: NCT06448793

Intervention type: DRUG
Intervention: Approved Non-small Cell Lung Cancer (NSCLC) therapies
Description: As prescribed by treating physician

Intervention type: DRUG
Intervention: Approved Non-small Cell Lung Cancer (NSCLC) therapies
Description: As prescribed by treating physician
Study: NCT05280561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHM
Description: DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
Study: NCT05265650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 in combination with ablative radiotherapy (SABR) and nivolumab
Description: Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Biopsies
Description: Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
Study: NCT03883945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: intradermal injection
Study: NCT05934448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab via iv, dosage and timing per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Chemotherapy
Description: Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor (CAR) Therapy Infusion
Description: Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
Study: NCT05693571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valera Smart Phone Application and Care Manager Dashboard
Description: Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
Study: NCT05742295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
Study: NCT05883488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted upper extremity rehabilitation
Description: The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
Study: NCT05074693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EASE app
Description: EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
Study: NCT05883488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
Study: NCT05845073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
Study: NCT05074693

Intervention type: OTHER
Group type: OTHER
Intervention: INSIGHT (Control) App
Description: A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos.
Study: NCT05260346

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: composition: Water, cranberry juice concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
Study: NCT06267404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iliopsoas Positional release therapy
Description: Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
Study: NCT05504382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: naproxen phonophoresis
Description: transmission of naproxen molecule by therapeutic ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: naproxen phonophoresis
Description: transmission of naproxen molecule by therapeutic ultrasound
Study: NCT05585190

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-Hour Stand Group
Description: Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 2 hours each work day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-Hour Stand Group
Description: Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 3 hours each work day.
Study: NCT06267404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
Study: NCT05350423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:Yttrium-Aluminum-Garnet
Description: The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
Study: NCT05499936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: 68Ga-FAPI were injected into the patients before the PET/CT scans
Study: NCT05683522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-omohyoidal Plane Block
Description: The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Plexus Block
Description: A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costoclavicular Block
Description: Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
Study: NCT06139263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a percussion massage gun (Compex Fix 2.0)
Description: Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment program
Description: In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment program
Description: In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
Study: NCT05143957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapablursen
Description: Sapablursen will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapablursen
Description: Sapablursen will be administered by SC injection.
Study: NCT05774678

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 1 (preoperative radiation hypofractionated)
Description: radiation schedules/regimens before your scheduled breast surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 1 (preoperative radiation hypofractionated)
Description: radiation schedules/regimens before your scheduled breast surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 (preoperative radiation conventionally fractionated)
Description: radiation schedules/regimens before your scheduled breast surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 (preoperative radiation conventionally fractionated)
Description: radiation schedules/regimens before your scheduled breast surgery
Study: NCT06487273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).

Intervention type: OTHER
Group type: OTHER
Intervention: Remote Physiotherapy
Description: Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Physiotherapy
Description: Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
Study: NCT05895058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery with 2D 4K laparoscopic imaging
Description: All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass surgery with 3D HD laparoscopic imaging
Description: All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
Study: NCT04594005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib+paclitaxel
Description: Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study.